Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

The observational prospective trial herein presented aimed at evaluating the efficacy of fulvestrant 500 mg in the treatment of endocrine sensitive advanced breast cancer patients from the real world setting. The primary end point was clinical benefit rate (CBR). Secondary end points were overall su...

Descripción completa

Detalles Bibliográficos
Autores principales: Moscetti, Luca, Fabbri, Maria Agnese, Natoli, Clara, Vici, Patrizia, Gamucci, Teresa, Sperduti, Isabella, Iezzi, Laura, Iattoni, Elena, Pizzuti, Laura, Roma, Carmine, Vaccaro, Angela, D’Auria, Giuliana, Mauri, Mariella, Mentuccia, Lucia, Grassadonia, Antonino, Barba, Maddalena, Ruggeri, Enzo Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589600/
https://www.ncbi.nlm.nih.gov/pubmed/28903361
http://dx.doi.org/10.18632/oncotarget.17262

Ejemplares similares

Ejemplares similares